Archive
Apitope and Merck Serono Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis (PDF)
13 January, 2009.
Fast Forward, LLC and Apitope International NV Announce $1 Million Partnership for Development of ATX-MS-1467 for Multiple Sclerosis (PDF)
23 December, 2008.
Apitope appoints Dr. Geoffrey Vernon as Chairman (PDF)
20 November, 2008.
Apitope raises EUR 10 million in a series A financing and signs strategic collaboration with UHasselt (PDF)
22 October, 2008.
ATX-MS-1467 - Positive Immunological data in Multiple Sclerosis Final Phase I/IIa data shows safety and tolerability, plus efficacy (PDF)
30 January, 2008.
ATX-MS-1467 completes dosing stage in a Phase I/IIa trial in Multiple Sclerosis patients (PDF)
5 November, 2007.
Apitope Named as Runner-up in Top British Bio Award for Innovation in Drug Discovery & Development (PDF)
10 July, 2007.
Apitope develops new approach to treat Multiple Sclerosis Discovery of Mechanism by which Peptide Therapy Protects Against Autoimmune Diseases (PDF)
18 September, 2006.
Apitope Technology (Bristol) Ltd. (Apitope®) announces Wellcome Trust funding and CEO appointment (PDF)
18 April, 2006.
